BioNTech vaccine 97% effective against symptomatic COVID-19 cases
- Economy
- Anadolu Agency
- Published Date: 05:19 | 11 March 2021
- Modified Date: 05:19 | 11 March 2021
US pharmaceutical firm Pfizer and its German biotech partner BioNTech announced Thursday that the real-world data by the Israeli Health Ministry demonstrates their vaccine's "high effectiveness," in preventing COVID-19.
The latest analysis by the Israeli Health Ministry using the public health data between Jan. 17 and March 6 showed that the Pfizer/BioNTech vaccine was at least 97% effective at preventing asymptomatic infections two weeks after the second vaccine dose.
The analysis also found that the vaccine's effectiveness was 94% against asymptomatic coronavirus infections.
"These findings are also important, as the data were generated at a time when the SARS-CoV-2 variant B.1.1.7 (also known as UK variant of coronavirus) was the dominant strain," co-founder and CEO of BioNTech Uğur Şahin said in a written statement.